As of Friday close, Globus Medical Inc.’s (NYSE:GMED) stock was up $4.08, moving up 6.93 percent to $62.93. The average number of shares traded per day over the past five days has been 904,840 shares. 3 times new highs have been achieved over the past 5 days, with a $4.24 gain in that time frame. In the last twenty days, the average volume was 641,650, while in the previous 50 days, it was 651,910.
Since last month, GMED stock rose 8.44%. Shares of the company fell to $55.12 on 07/14/22, the lowest level in the past month. A 52-week high of $84.23 was reached on 04/21/22 after having rallying from a 52-week low of $52.60. Since the beginning of this year, GMED’s stock price has dropped by -12.84% or -$9.27, and marked a new high 10 times. However, the stock has declined by -25.29% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Globus Medical Inc. (GMED) last reported insider trading activity 109 days ago on Apr 19. Davidar David D, the Director of the company, disposed of 31,500 shares for $78.03 on Apr 19. It resulted in a $2,458,071 divestment by the insider. Huller Kelly sold 2,500 shares at an average price of $75.58 on Apr 08. The insider now owns 0 shares following the transaction. On Mar 15, Director TOBIN JAMES R sold 8,850 shares at $65.47 apiece. The transaction was valued at $579,418.
Right now, Globus Medical Inc. (GMED) has a P/E ratio of about 46.10. The stock’s beta is 1.14. Besides these, the trailing price-to-sales (P/S) ratio of 6.79, the price-to-book (PB) ratio of 3.58, and the price-to-cash flow ratio of 33.61 may also be considered.
In the three months ended March 30, Globus Medical Inc.’s quick ratio stood at 4.70, while its current ratio was 6.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 74.70% percent. In the year ended March 30, operating margins totaled 17.00%. Based on annual data, GMED earned $718.88 million in gross profit and brought in $958.1 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.10%. Return on equity (ROE) for the past 12 months was 8.20%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. GMED’s revenue rose 1.39% during the quarter, while net income inched up to $230.55 million. While analysts expected Globus Medical Inc. to report $0.47 quarterly earnings, the actual figure was $0.42 per share, beating the consensus estimate by -10.60%. During the quarter, the company generated $86.22 million in EBITDA. The liabilities of Globus Medical Inc. were 215.62 million at the end of its most recent quarter ended March 30. The value of shareholders’ equity is $99.52 million.
This quick technical analysis looks at Globus Medical Inc.’s (GMED) price momentum. With a historical volatility rate of 37.90%, the RSI 9-day stood at 71.91% on 05 August.
With respect to its five-day moving average, the current Globus Medical Inc. price is up by +7.22% percent or $4.24. At present, GMED shares trade +9.25% above its 20-day simple moving average and -2.34% percent below its 100-day simple moving average. However, the stock is currently trading approximately -3.89% below its SMA50 and -18.50% below its SMA200.
Stochastic coefficient K was 75.78% and Stochastic coefficient D was 78.84%, while ATR was 2.17. Given the Stochastic reading of 80.49% for the 14-day period, the RSI (14) reading has been calculated as 65.04%. As of today, the MACD Oscillator reading stands at 0.93, while the 14-day reading stands at 1.62.
Globus Medical Inc. (GMED) has been rated Overweight by analysts. According to 0 brokerage firms, GMED is a sell, and 4 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Globus Medical Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $71.00, the current consensus forecast for the stock is $62.00 – $90.00. Based on these forecasts, analysts predict Globus Medical Inc. (GMED) will achieve an average price target of $71.42.